-
1دورية أكاديمية
المؤلفون: Swisher, EM, Kwan, TT, Oza, AM, Tinker, A, Ray-Coquard, I, Oaknin, A, Coleman, RL, Aghajanian, C, Konecny, GE, O'Malley, DM, Leary, A, Provencher, D, Welch, S, Chen, L-M, Hendrickson, AEW, Ma, L, Ghatage, P, Kristeleit, RS, Dorigo, O, Musafer, A, Kaufmann, SH, Elvin, JA, Lin, D, Chambers, SK, Dominy, E, Lan-Thanh, V, Goble, S, Maloney, L, Giordano, H, Harding, T, Dobrovic, A, Scott, CL, Lin, KK, McNeish, IA
العلاقة: pii: 10.1038/s41467-021-22582-6; Swisher, E. M., Kwan, T. T., Oza, A. M., Tinker, A., Ray-Coquard, I., Oaknin, A., Coleman, R. L., Aghajanian, C., Konecny, G. E., O'Malley, D. M., Leary, A., Provencher, D., Welch, S., Chen, L. -M., Hendrickson, A. E. W., Ma, L., Ghatage, P., Kristeleit, R. S., Dorigo, O. ,. McNeish, I. A. (2021). Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). NATURE COMMUNICATIONS, 12 (1), https://doi.org/10.1038/s41467-021-22582-6Test.; http://hdl.handle.net/11343/278177Test
-
2دورية أكاديمية
المؤلفون: Swisher, EM, Kwan, TT, Oza, AM, Tinnker, AV, Ray-Coquard, I, Oaknin, A, Coleman, RL, Aghajanian, C, Konecny, GE, O'Malley, DM, Leary, A, Provencher, D, Welch, S, Chen, L-M, Wahner Hendrickson, AE, Ma, L, Ghatage, P, Kristeleit, RS, Dorigo, O, Musafer, A, Kaufmann, SH, Elvin, JA, Lin, DI, Chambers, SK, Dominy, E, Vo, L-T, Goble, S, Maloney, L, Giordano, H, Harding, T, Dobrovic, A, Scott, CL, Lin, KK, McNeish, I
المساهمون: Imperial College Healthcare NHS Trust- BRC Funding, Cancer Research UK, Ovarian Cancer Action
العلاقة: Nature Communications; http://hdl.handle.net/10044/1/88649Test; RDB01; RG71079; n/a
النص الكامل